Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 8/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.42 |
| ▸ | TERT | O14746 | 8/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.36 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.36 |
| ▸ | TCF7L2 | Q9NQB0 | 1/20 | 0.36 |
| ▸ | POT1 | Q9NUX5 | 3/20 | 0.35 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12177214 | 0.99 | HRH3 (0.42) | HRH3KCNH2TERTKMT2AP2RY12 | |
| SCHEMBL13182892 | 0.96 | HRH3 (0.43) | HRH3KCNH2TERTKMT2APOT1 | |
| SCHEMBL14113594 | 0.95 | HRH3 (0.42) | HRH3KCNH2TERTPOT1 | |
| SCHEMBL12161498 | 0.94 | P2RY12 (0.43) | HRH3KCNH2TERTKMT2AP2RY12 | |
| SCHEMBL9922379 | 0.94 | P2RY12 (0.42) | HRH3KCNH2TERTKMT2AP2RY12 | |
| SCHEMBL12177261 | 0.94 | KCNH2 (0.37) | HRH3KCNH2KMT2AP2RY12MCHR1 | |
| SCHEMBL9923217 | 0.90 | HRH3 (0.47) | HRH3KCNH2TERTP2RY12CTNNB1 | |
| SCHEMBL9922744 | 0.90 | HRH3 (0.42) | HRH3KCNH2TERTKMT2AP2RY12 | |
| SCHEMBL12177420 | 0.90 | HRH3 (0.46) | HRH3KCNH2TERTP2RY12 | |
| SCHEMBL9922202 | 0.90 | HRH3 (0.42) | HRH3KCNH2TERTKMT2AP2RY12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120149688-A1 | PLATELET ADP RECEPTOR INHIBITORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
| US-20080194597-A1 | Asulfonyl(urea, thiourea, guanidine, cyanoguanidine) compounds; cardiovascular disorders; thrombosis | PORTOLA PHARMACEUTICALS, INC. (US) | 2008-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194597-A1 | Asulfonyl(urea, thiourea, guanidine, cyanoguanidine) compounds; cardiovascular disorders; thrombosis | PIGS, GP6, ASGR1 | HRH3 2498/4885KCNH2 685/4885TERT 2357/4885 |
| US-20120149688-A1 | PLATELET ADP RECEPTOR INHIBITORS | TBXA2R, GP6, P2RY6 | HRH3 1858/4885KCNH2 1064/4885TERT 2585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.